Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population. Though vorasidenib can be administered from 12 years old, VIOLETA focuses on adult patients with IDH1- or IDH2-mutant WHO grade 2 glioma who receive vorasidenib following surgery according to the current SmPC. Thus, VIOLETA will evaluate for the first-time treatment with vorasidenib in German clinical routine. To gain knowledge about how vorasidenib treatment affects patients' well-being, the primary objective of the study is to assess patients' quality of life. Further patient-relevant endpoints addressed by this study will include seizure burden, PFS, Objective Response Rate (ORR), TTNI, safety as well as factors affecting treatment decision making.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vorasidenib | Drug | oral, first-in-class, dual inhibitor of mIDH 1 and 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate Quality of Life (QoL) by the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire over the course of treatment | Evaluate QoL by the FACT-Br questionnaire over the course of treatment. Change from baseline in the FACT-Br total score over time. The FACT-Br total score ranges from 0 to 200, with higher scores indicating better quality of life. | baseline, up to 72 months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate Quality of Life (QoL) by using the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire at start and during course of vorasidenib treatment | Evaluate QoL by using the FACT-Br questionnaire at start and during course of vorasidenib treatment. Change from baseline over time for all other scales of the FACT-Br. For all scales, the higher the score the better quality of life. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (at least 40 kg) with predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| iOMEDICO | Contact | +49761152420 | information@iomedico.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg | Recruiting | Heidelberg | Germany |
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| C000716758 | vorasidenib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: Proportion of patients with baseline seizure activity | Proportion of patients with baseline seizure activity is defined as at least 1 seizure in the previous 30 days prior to vorasidenib treatment start | baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: event rate of seizures | Exposure adjusted event rate of seizures according to patient-reported outcome (patient diary) | baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: event rate of seizures with loss of consciousness | Exposure adjusted event rate of seizures with loss of consciousness according to PRO (patient diary) | baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures | Exposure adjusted incidence rate of seizures according to patient-recorded outcome | baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures with loss of consciousness | Exposure adjusted incidence rate of seizures according to patient-reported outcome | baseline, up to 72 months |
| Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures | Change from baseline of seizures reported by the patients during course of treatment | max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up) |
| Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures with loss of consciousness | Change from baseline of seizures with loss of consciousness reported by the patients during course of treatment | baseline, up to 72 months |
| Assess effectiveness in routine treatment: Progression-free survival | PFS ist defined as time interval measured from the day of first vorasidenib administration to first progression or death, whichever comes first. Patients without tumor progression or death at the time of analysis will be censored at their date of last contact. | baseline, up to 72 months |
| Assess effectiveness in routine treatment: Overall Survival (OS) | OS is defined as the time interval measured form the day of first vorasidenib administration to time of death from any cause. Time to last contact will be used if a patient has no documented date of death and OS for the patient will be considered censored. | baseline, up to 72 months |
| Assess effectiveness in routine treatment: Objective response rate (ORR) | ORR is defined as the proportion of patients achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) as best response. | max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up) |
| Assess effectiveness in routine treatment: Disease Control Rate (DCR) | DCR is defined as proportion of patients with Complete Response, Partial Response, Minor Response or Stable Disease as best response. | baseline, up to 72 months |
| Assess effectiveness in routine treatment: Best response | Best response is defined as Complete Response (CR), Partial Response (PR), Minor Response (MR), Stable Disease (SD), or Progressive Disease (PD)) | baseline, up to 72 months |
| Assess effectiveness in routine treatment: Time to next intervention (TTNI) | Time to next intervention is defined as time from first administration of vorasidenib until initiation of next intervention (i.e., subsequent antineoplastic treatment, surgery, chemotherapy or radiotherapy) or death, whichever comes first. | baseline, up to 72 months |
| Assess drug safety: Incidence of (serious) adverse events ((S)AEs) | Incidence of (serious) AEs ((S)AEs) as characterized by type, frequency, severity and seriousness. | Baseline up to 30 days after vorasidenib treatment |
| Assess drug safety: Incidence of (serious) adverse drug reactions ((S)ADRs) | Incidence of (serious) adverse drug reactions ((S)ADRs) as characterized by type, frequency, severity and seriousness. | Baseline up to 30 days after vorasidenib treatment |
| Assess drug safety: Incidence of seizures reported as treatment-emergent adverse events (TEAEs) | Treatment-emergent adverse events (TEAE) are adverse events that were not present before medical treatment, or a pre-existing event that worsens in intensity or frequency during vorasidenib treatment and the following 30 days. | Baseline up to 30 days after vorasidenib treatment |
| Assess parameters of physicians' treatment decision making using a questionnaire | Frequency of distinct parameters affecting therapy choice; questionnaire completed by treating physician. | Baseline |
| Duration of treatment with vorasidenib | Describe treatment reality in detail: Duration of treatment with vorasidenib | baseline, up to 72 months |
| Frequency of treatment modifications with reasons | Describe treatment reality in detail: Frequency of treatment modifications with reasons | baseline, up to 72 months |
| Time to start of vorasidenib treatment after initial diagnosis | Describe treatment reality in detail: Time to start of vorasidenib treatment after initial diagnosis | Baseline |
| Time to start of vorasidenib treatment after surgery | Describe treatment reality in detail: Time to start of vorasidenib treatment after surgery | Baseline |
| Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies) | Describe treatment reality in detail: Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies) | baseline, up to 72 months |
| Anti-epileptic medication: Proportion of patients with anti-epileptic drug (AED) treatment at baseline | Proportion of patients with anti-epileptic drug treatment at baseline (i.e. 30 days prior treatment) | baseline, up to 72 months |
| Anti-epileptic medication: Proportion of patients with AED treatment during treatment | Proportion of patients with anti-epileptic drug treatment during treatment | baseline, up to 72 months |
| Anti-epileptic medication: Type of AED | Anti-epileptic medication during course of treatment | baseline, up to 72 months |
| Anti-epileptic medication: Doses of AED | Doses of anti-epileptic medication over the course of time | baseline, up to 72 months |
| Anti-epileptic medication: AED modifications | Type of anti-epileptic medication modifications | baseline, up to 72 months |
| Anti-epileptic medication: Reasons for AED modifications | Anti-epileptic medication modifications with reasons thereof | baseline, up to 72 months |
| Anti-epileptic medication: Frequency of patients under AED treatment after End of Treatment (EOT) of vorasidenib | Frequency of patients under AED treatment after EOT of vorasidenib (incl. dose) | from end of treatment to end of study, up to 72 months |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |